At the time of this writing, liraglutide is the only GLP-1 RA with a labeled indication to reduce the risk of major adverse cardiovascular events (MACE), yet several other GLP-1 RAs have shown significant reduction in MACE, as summarized in Table 2
This milestone marks the initiation of the first Phase 3 clinical trial of Bofanglutide injection worldwide for the treatment of T2DM
Liraglutide attenuates diabetic cardiomyopathy via the ILK/PI3K/AKT/PTEN signaling pathway in rats with streptozotocin-induced type 2 diabetes mellitus
Approval by the Food and Drug Administration is likely years away for most
Sensitization of trigeminal caudalis neuronal responses to intraoral acid and salt stimuli and desensitization by nicotine
Individual results vary based on starting weight, metabolic health, adherence to lifestyle modifications, genetic factors, and concurrent medications